Idiosyncratic drug induced liver injury (DILI) is a rare but potentially serious liver disorder and a major cause of signifi cant liver injury. Limited data exist on racial differences in DILI incidence, presentation, and course.
INTRODUCTION
Idiosyncratic drug induced liver injury is a rare but clinically important entity with a recent population frequency of 15 events per 100,000 inhabitants in the Western world ( 1 ) . Th e prompt discontinuation of the implicated agent improves the liver injury event in the majority suff ering from drug induced liver injury (DILI), but there is a high rate of hospitalization and rarely, acute liver failure leading to liver transplantation or death ( 2, 3 ) . Furthermore, recent reports suggest that sizable number of acute DILI events may lead to chronic liver disease with demonstrable long-term histological damage ( 3, 4 ) . A recent report from the DILIN observed that severe cutaneous reactions accompanied one percent of DILI events and were associated with high mortality rate ( 2 ) .
Established in 2003, the United States Drug-Induced Liver Injury Network (DILIN) is conducting a prospective study of Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians individuals who are ≥2 years of age with suspected DILI at several clinical centers across the United States ( 5 ) . Individuals enrolled into this study are from varying ethnic and racial backgrounds and the DILIN Prospective Study has enrolled over 100 individuals who are of self-reported African-American race. Th is diversity provides an opportunity to characterize the causative agents and the characteristics and outcomes of DILI in this important demographic. During the conduct of this study, we anecdotally observed some diff erences in terms of causative agents or skin reactions among various racial and ethnic groups. Th ere is a suggestion in the literature that certain adverse drug reactions (ADRs) have different frequency and clinical phenotypes in diff erent racial and ethnic groups. For example, it was recently observed that AfricanAmericans are at signifi cantly higher risk for allopurinol-induced Stevens-Johnson syndrome, an ADR which shares overlapping features with DILI ( 6 ) . In a report from the United States Acute Liver Failure Study Group (ALFSG), Forde et al. ( 7 ) have shown that blacks (24.4%) were more likely to have acute liver failure due to drugs than whites (14.9%, P =0.015). Recent studies have also highlighted racial and ethnic diff erences in the prevalence and characteristics of nonalcoholic fatty liver disease ( 8, 9 ) . Th is prompted us to carefully analyze DILI in self-reported AfricanAmericans enrolled in the DILIN Prospective Study. Th e objectives of this report are to compare the profi le of causative agents, the clinical characteristics and the outcomes of DILI in African Americans in comparison to Caucasians.
METHODS
Th e DILIN Prospective Study (NCT 00345930) is conducted by the United States Drug Induced Liver Injury Network which is funded as a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. DILIN consists of 6-8 medical centers, a central data coordinating center and a sample repository. Th e DILI Prospective Study design, method of causality assessment, and various scoring systems have been described in detail elsewhere ( 5 ) . Th e study was approved by the appropriately convened institutional review boards at the participating clinical centers and data coordinating center as well as by a Data Safety and Monitoring Board appointed for this purpose by the NIDDK. All participants provided written informed consent before enrollment. Th e DILIN Prospective Study has been the source for multiple publications on topics which ranged from overall patient population characteristics to phenotypes and sub-phenotypes and select implicated agents (10) (11) (12) (13) (14) (15) (16) (17) . Participants who form the basis for this report were included in other reports published by the DILIN. All participants completed a questionnaire that captured self-reported racial and ethnic information. Cases of DILI that underwent formal causality assessment and were judged to be defi nite, highly likely, or probable were eligible for inclusion in this analysis. 
Data management and analyses

RESULTS
Between September 2014 and February 2016, 1,620 individuals were enrolled into the DILIN Prospective Study and 1,455 had undergone 6 months of follow-up and formal causality assessment of whom 1,182 were scored as defi nite, highly likely, or probable. Th ese confi rmed DILI cases included 144 individuals who selfreported their ethnicity and race as non-Hispanic Black or AfricanAmerican and 841 who reported being non-Hispanic Whites or Caucasians. Th e remaining 191, reported their ethnicity and race as Asian ( n =41), Hispanic ( n =86), or other ( n =36), or did not provide ethnic and racial information ( n =6). Th e construction of the patient cohort for analysis is shown diagrammatically in Figure 1 . Th e analysis was limited to cases occurring among nonHispanic whites (Caucasians) and blacks (African Americans).
A comparison of the demographic, clinical, and biochemical features of the two study groups are shown in Table 1 . In comparison to Caucasians, African-Americans with DILI tended to be younger with signifi cantly higher body mass index (BMI) and higher prevalence of diabetes but lower frequency of prior drug allergies or alcohol consumption history. Gender and the frequency of preexisting liver disease were not diff erent between two groups. Th ere were more African-Americans with DILI who lacked any health insurance or were without at least a high school education.
Th e fi ve leading therapeutic classes and top 10 single prescription agents implicated among the 144 African-Americans and 841 Caucasians are shown in Table 2 . In general, there were no signifi cant diff erences in the classes of agents implicated between two groups, with antimicrobials, herbal and dietary supplements, cardiovascular system agents, and central nervous system agents being the most commonly implicated classes. However, there appeared important diff erences in the individual agents that were implicated in causing DILI between the African-American and Caucasian groups ( Table 2 ) . Th e combination of trimethoprim and sulfamethoxazole (TMP/SMZ) was the most common agent implicated in causing DILI in African-Americans (7.6%) and its frequency was signifi cantly higher than in Caucasians (3.6%, P =0.04). In contrast, the combination of clavulanic acid with amoxicillin (Clav/Amox) was the most commonly implicated agent in DILI among Caucasians (13.4%), but it ranked fourth and its frequency was signifi cantly lower among African-Americans LIVER VOLUME 112 | SEPTEMBER 2017
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(4.1%, P <0.001). Additionally, compared to Caucasians, AfricanAmericans had signifi cantly higher frequency of liver injury due to phenytoin (4.8 vs. 0.8%, P =0.002), methyldopa (4.1 vs. 0.5%, P =0.001), and allopurinol (2.7 vs. 0.4%, P =0.01). Th ese three agents ranked 3rd, 5th and 8th among African-Americans, but only 24th, 41th and 51th among Caucasians.
Th e time between initiating the implicated medication or herbal agent and onset of DILI (latency) and the interval between earliest symptoms of liver injury and discontinuation of the suspected medication (delay in stopping) were not diff erent between the African-Americans and Caucasian groups. In addition, the degrees of likelihood as assessed by RUCAM, DILIN causality scores and DILIN causality categories were similar between the two groups ( Table 3 ) . Th e R-ratio or the patterns of liver injury at presentation were minimally diff erent between the two groups, although there was a trend towards the "mixed hepatocellular-cholestatic" pattern of liver injury being less frequent among African-Americans with DILI than Caucasians (17 vs. 24%, P =0.078). Although the degree of elevation of serum enzymes at onset of DILI was not diff erent between the two groups, peak levels of ALT and INR were signifi cantly higher in African-Americans than in Caucasians, and the peak total bilirubin was higher but these diff erences were not statistically signifi cant. Th e time to improvement in serum liver biochemical tests was similar in the two racial groups.
Assessment of severity using the DILIN scoring system indicated that the liver injury was on average more severe among Causality score of definite, highly likely, or probable N=1,182
Missing race and ethnicity information (n=6)
Total with race and ethnicity information N=1,176
Non-Hispanic White N=841
Non-Hispanic Black N=144
Non-Hispanic Black and Whites N=985 
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African-Americans than Caucasians ( Table 3 ). Th us, the mean DILIN severity scores were signifi cantly higher in AfricanAmericans than Caucasians (3.0 vs. 2.6), and the distribution of scores was skewed to a higher frequency of severe and fatal cases among African-Americans compared to Caucasians (34 vs. 24%). Among age, BMI, and diabetes, only BMI had statistically signifi cant univariate relationship with the DILIN severity score. When we controlled for BMI, the relationship between AfricanAmerican and DILIN severity score statistically signifi cant (OR 1.98, 95% CI: 1.42-2.75, P <0.001). Th e frequency of severe liver injury leading to death or requiring liver transplantation was higher in African-Americans (10.2%) than in Caucasians (5.8%).
Among age, BMI, and diabetes, both age and BMI had statistically signifi cant univariate relationship with the DILIN severity score. When we controlled for age and BMI, the relationship between African-American and the likelihood of death or liver transplantation statistically signifi cant (OR 2.12, 95% CI: 1.12-3.9, P =0.02). In addition, chronicity was more frequent in the DILIN cases among African-Americans than Caucasians (24 vs. 16%), but this diff erence was of borderline statistical signifi cance ( P =0.06). Finally, severe cutaneous reactions occurred in 0.6% of patients in this cohort and were more frequent in African-Americans than Caucasians (2.1 vs. 0.36%, P =0.048). Two of the cases with severe cutaneous reactions were attributed to lamotrigine ( n =2) and one each to carbamazepine, azithromycin, and nitrofurantoin.
Th ere were no signifi cant diff erences in the latency, liver biochemical tests at presentation or their peak values, R-ratio, or outcomes (such as death or liver failure needing liver transplantation) of liver injury caused by TMP/SMX, amoxicillin-clavulanate, isoniazid, nitrofurantoin, or phenytoin between African-Americans and Caucasians. Although the severity of liver injury due to TMP/ SMX, amoxicillin-clavulanate, isoniazid, or nitrofurantoin was not diff erent between African-Americans and Caucasians, there were signifi cantly higher number of severe/fatal liver injury events due to phenytoin in African-Americans than in Caucasians (86 vs. 14%, P =0.008).
DISCUSSION
Our study adds to a growing body of literature showing racial and ethnic diff erences in the frequency and nature of ADRs. A recent systematic review found no consistent relationship between race and ADRs in general but noted that certain racial groups may be at higher risk for ADRs due to certain classes of agents ( 18 ) . Asians were found to be higher risk for ADRs from oral anticoagulants, and similarly liver biochemistries at DILI presentation were not diff erent between two groups. Th is suggests that greater severity and worse outcomes associated with DILI in African-Americans is not likely due to a delay in seeking care by African-Americans. Furthermore, except for phenytoin, none of the other common causes of DILI in this cohort (TMP/SMX, isoniazid, nitrofurantoin, herbal and dietary supplements, or amox-clav) per se were associated with more severe liver injury in African-Americans. Th e higher frequency of severe cutaneous reactions we observed in African-Americans with DILI is intriguing. Th is does not appear to be diff erences in the DILI causative agents between two groups. Antiepileptic drugs are known to be associated with severe cutaneous reactions but the frequency of liver injury due to anti epileptics was not diff erent between African-Americans and Caucasians was not diff erent. TMP/SMZ and allopurinol are known to cause severe cutaneous reactions. Although there were more cases of TMP/SMZ and allopurinol associated liver injury among African-Americans, none were associated with severe cutaneous reactions. It needs to be explored if African-Americans have an increased genetic predisposition to severe cutaneous reactions.
In summary, this report summarizes causative agents, clinical aspects, and outcomes of well characterized DILI in a large cohort of African-Americans. Th e causative agents, certain clinical features (e.g., frequency of severe cutaneous reactions) and outcomes of DILI are distinct in African-Americans. We believe that our observations add to the growing body of literature on DILI. It is of value to providers to know that (a) some compounds are more likely to cause DILI in AA than in Caucasian (may infl uence their prescription patterns) and (b) DILI in African Americans may have worse outcomes and thus they may be followed closely with intensifi ed follow-up. Further research is needed to better understand the basis for these diff erences. Larger population based studies should be conducted to confi rm if African-Americans are at increased risk (or lower risk) for liver injury from well-recognized hepatotoxic medications. Adequately powered genomic studies with optimal control groups should also be conducted to understand if there are genetic factors that at least in part explain our observations.
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Indiana University-Purdue: Naga Chalasani, MD, PI; Marwan S. whereas blacks were at higher risks from antidiabetic agents and whites from opiate analgesics ( 18 ) . In a study of United States Vital Statistics, deaths due to ADRs were signifi cantly more frequent in African-Americans than Caucasians, Hispanics, or Asians ( 19 ) . Asians and blacks appear to be at signifi cantly higher risk for severe cutaneous reactions due to allopurinol and this phenomenon is strongly associated with higher frequency of HLA-B*5801 in Asians and blacks ( 6 ) . A few studies investigated the relationship between race and ethnicity and hepatotoxicity from antituberculosis (anti-TB) medications (20) (21) (22) . In the United States Public Health Service study published in 1979, the frequency of liver injury due to anti-TB medications was signifi cantly lower in African-American males compared to white males, but there existed no such diff erence among females ( 20 ) . However, this observation was not reproduced in subsequent studies ( 21, 22 ) . In our study, we did not fi nd signifi cant diff erence in the frequency of liver injury due to isoniazid between African-Americans and Caucasians (6.2 vs. 3.6%, P =0.16).
Th e major causes of DILI among African Americans in the DILIN Prospective Study were somewhat distinctive. Compared to common causes among Caucasians, the major causes of DILI among African-Americans were more likely to be agents that are associated with acute and sometimes severe hypersensitivity reactions or those typically present with a "mixed hepatocellularcholestatic" pattern of injury. Th us, TMP/SMZ, phenytoin, and allopurinol are all associated with immune-allergic type of injury that is commonly "mixed", and methyldopa with an autoimmune phenotype that is commonly hepatocellular. When, analyzed by individual agents, African-Americans, who made up 13% of the DILIN cohort, represented 27% of TMP/SMZ, 50% of phenytoin, 43% of allopurinol and 55% of methyldopa cases. In contrast, African-Americans were underrepresented in the cases of amox-clav associated liver injury. Amox-clav has repeatedly been shown to be the most common cause of DILI in the western world ( 2, 10, 23, 24 ) . It is interesting to note that the frequency of HLA A*02:01 and HLA DRB1*15:01 alleles which previously have been reported as risk factors for liver injury due to amoxicillin-clavulanate is much lower in African-Americans than in Caucasians (25) (26) (27) . In one study, the frequency of HLA A*02:01 among Caucasians residing in the United States was 27.2%, whereas its frequency in African-Americans was only 12.1% ( 26 ) . Similarly, the frequency of HLA DRB1*15:01 in African-Americans was only 3% compared to 25% among Caucasians residing in the United States ( 27 ) . However, the underrepresentation of amoxicillin-clavulanate induced liver injury among African-Americans could be due to other factors such as diff erences in underlying infections for which this medication was prescribed, or diff erences in prescription patterns of health care providers.
Th e liver injury in African-Americans was more severe as refl ected by higher DILIN severity scores and more frequent hospitalization and was associated with higher frequency of worse outcomes such as liver related mortality/liver transplantation and chronic DILI. Th e reasons for this phenomenon are unclear. Th e duration between earliest DILI symptoms and stopping the implicated agent was comparable between the two groups
